190 related articles for article (PubMed ID: 6197309)
21. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.
Paterson IA; Davis BA; Durden DA; Juorio AV; Yu PH; Ivy G; Milgram W; Mendonca A; Wu P; Boulton AA
Neurochem Res; 1995 Dec; 20(12):1503-10. PubMed ID: 8789614
[TBL] [Abstract][Full Text] [Related]
22. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels.
Griebel G; Curet O; Perrault G; Sanger DJ
Neuropharmacology; 1998 Jul; 37(7):927-35. PubMed ID: 9776388
[TBL] [Abstract][Full Text] [Related]
23. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
[TBL] [Abstract][Full Text] [Related]
24. CGP 4718 A, a new potential antidepressant with a dual mode of action.
Waldmeier PC; Tipton KF; Bernasconi R; Felner AE; Baumann PA; Maitre L
Eur J Pharmacol; 1984 Dec; 107(1):79-89. PubMed ID: 6526072
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fuller RW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
[TBL] [Abstract][Full Text] [Related]
27. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat.
Garrett MC; Soares-da-Silva P
Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970
[TBL] [Abstract][Full Text] [Related]
28. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
Garrick NA; Scheinin M; Chang WH; Linnoila M; Murphy DL
Biochem Pharmacol; 1984 May; 33(9):1423-7. PubMed ID: 6203542
[TBL] [Abstract][Full Text] [Related]
30. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS
Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486
[TBL] [Abstract][Full Text] [Related]
31. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
32. Effect of chronic ritanserin or clorgyline on amine and metabolite levels in rat frontal cortex.
Twist EC; Mitchell SN; Corn TH; Campbell IC
Eur J Pharmacol; 1991 Apr; 196(2):157-60. PubMed ID: 1908389
[TBL] [Abstract][Full Text] [Related]
33. Ethanol concentration induces production of 3,4-dihydroxyphenylacetic acid and homovanillic acid in mouse brain through activation of monoamine oxidase pathway.
Jamal M; Ito A; Miki T; Suzuki S; Ohta KI; Kinoshita H
Neurosci Lett; 2022 Jun; 782():136689. PubMed ID: 35598694
[TBL] [Abstract][Full Text] [Related]
34. Regional action of brofaromine on rat brain MAO-A and MAO-B.
Gerardy J; Dresse A
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1141-55. PubMed ID: 9829294
[TBL] [Abstract][Full Text] [Related]
35. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
Bel N; Artigas F
Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
[TBL] [Abstract][Full Text] [Related]
36. Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study.
Adachi YU; Watanabe K; Higuchi H; Satoh T; Vizi ES
Eur J Pharmacol; 2001 Jun; 422(1-3):61-8. PubMed ID: 11430914
[TBL] [Abstract][Full Text] [Related]
37. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.
Fowler CJ; Benedetti MS
J Neurochem; 1983 Jun; 40(6):1534-41. PubMed ID: 6406646
[TBL] [Abstract][Full Text] [Related]
38. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
[TBL] [Abstract][Full Text] [Related]
39. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
Severina IS; Klimova GI; Nersisian AA
Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
[TBL] [Abstract][Full Text] [Related]
40. The monoamine oxidase inhibiting properties of CGP 11305 A.
Waldmeier PC; Felner AE; Tipton KF
Eur J Pharmacol; 1983 Oct; 94(1-2):73-83. PubMed ID: 6653660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
